Anti-DAP3 抗体 (ab2637)
Key features and details
- Goat polyclonal to DAP3
- Suitable for: ICC/IF, WB
- Reacts with: Human
- Isotype: IgG
製品の概要
-
製品名
Anti-DAP3 antibody
DAP3 一次抗体 製品一覧 -
製品の詳細
Goat polyclonal to DAP3 -
由来種
Goat -
特異性
This antibody is expected to recognise both human isoforms of this protein. -
アプリケーション
適用あり: ICC/IF, WBmore details -
種交差性
交差種: Human -
免疫原
Synthetic peptide corresponding to Human DAP3 aa 387-398 (C terminal).
Sequence:NPSLLERHCAYL
(Peptide available asab22922) -
ポジティブ･コントロール
- WB: HeLa and HepG2 cell lysate and human kidney tissue lysate. ICC/IF: MCF7 cells.
-
特記事項
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.5% Tris, 0.5% BSA -
Concentration information loading... -
精製度
Immunogen affinity purified -
特記事項（精製）
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab2637の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| ICC/IF |
Use a concentration of 3 - 10 µg/ml.
|
|
| WB |
Use a concentration of 1 - 3 µg/ml. Predicted molecular weight: 46 kDa.
1 hour primary incubation is recommended for this product. |
| 特記事項 |
|---|
|
ICC/IF
Use a concentration of 3 - 10 µg/ml. |
|
WB
Use a concentration of 1 - 3 µg/ml. Predicted molecular weight: 46 kDa. 1 hour primary incubation is recommended for this product. |
ターゲット情報
-
機能
Involved in mediating interferon-gamma-induced cell death. -
組織特異性
Ubiquitous. -
細胞内局在
Mitochondrion. - Information by UniProt
-
参照データベース
- Entrez Gene: 7818 Human
- Omim: 602074 Human
- SwissProt: P51398 Human
- Unigene: 516746 Human
-
別名
- 28S ribosomal protein S29 antibody
- 28S ribosomal protein S29 mitochondrial antibody
- bMRP10 antibody
see all
画像
-
Western blot - Anti-DAP3 antibody (ab2637)Anti-DAP3 antibody (ab2637) at 0.3 µg/ml + Human kidney tissue lysate in RIPA buffer at 30 µg
Predicted band size: 46 kDaDetected using chemiluminescence.
-
Immunocytochemistry/ Immunofluorescence - Anti-DAP3 antibody (ab2637)Immunocytochemistry/Immunofluorescence analysis of MCF7 cells labelling DAP3 with ab2637 at 10 µg/ml. Cells were paraformaldehyde fixed and permeabilized with 0.15% triton. Primary antibody icubation was for 1 hour followed by incubation with an Alexa Fluor® 488-conjugated secondary antibody at 2 µg/ml. DAPI nuclear counterstain was used.
Negative control: Unimmunized goat IgG (10 µg/ml) followed by an Alexa Fluor® 488-conjugated secondary antibody (2 µg/ml).
-
Western blot - Anti-DAP3 antibody (ab2637)All lanes : Anti-DAP3 antibody (ab2637) at 0.3 µg/ml
Lane 1 : HeLa cell lysate in RIPA buffer
Lane 2 : HepG2 cell lysate in RIPA buffer
Lysates/proteins at 30 µg per lane.
Predicted band size: 46 kDaDetected using chemiluminescence.
-
Western blot - Anti-DAP3 antibody (ab2637)All lanes : Anti-DAP3 antibody (ab2637) at 1 µg/ml (for 1 hour)
Lane 1 : HeLa cell lysate in RIPA buffer - control
Lane 2 : HeLa cell lysate in RIPA buffer - after siRNA mediated DAP3 knock-down expression
Lysates/proteins at 35 µg per lane.
Predicted band size: 46 kDaLevel of knock-down relative to actin expression level determined by RT-PCR.
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (2)
ab2637 は 2 報の論文で使用されています。
- Han J et al. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer. Nat Commun 13:1793 (2022). PubMed: 35379802
- Han J et al. Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. Sci Adv 6:eaba5136 (2020). PubMed: 32596459
